Digital Conference Resources
FYR’s AI-powered EVO-Platform™ reveals groundbreaking genomics, transcriptomics, and proteomics insights from extracellular vesicles (EVs). Explore the materials below for more details on our innovative platform and solutions. Want to learn more? Email us at bd@fyr.bio or connect with us through our contact form.
Available for Download
-
AACR 2025 (Poster)
Proteomic profiling of tumor-derived extracellular vesicles enables early lung cancer detection.
View Poster -
AACR 2025 (Poster)
Transcriptional profiling of extracellular vesicle subpopulations enables liquid biopsy-based brain tumor classification.
View Poster -
AACR 2025 (NSCLC Flyer)
Utilization of tumor-derived extracellular vesicles for patient stratification and biomarker discovery.
View Flyer -
EV-Omics Background (Flyer)
We are revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, better trials, better drugs and better outcomes.
View Flyer -
Supporting Drug Development (Flyer)
FYR's EVO Platform provides ultrasensitive multiomic biomarker discovery to support drug development.
View Flyer -
Neuro-Oncology Data (Flyer)
We have developed a clinically applicable, multi-omic EV subpopulation interrogation pipeline that robustly profiles tumor and brain derived EVs (TDEVs and BDEVs) in biofluids.
View Flyer -
NSCLC Case Study (Flyer)
FYR's panel enables high sensitivity, high specificity detection of Stage 1 and 2 NSCLC samples.
View Flyer -
SNO 2024 (Poster)
Utilization of Tumor-derived Extracellular Vesicles for Patient Stratification and Biomarker Discovery.
View Poster -
ASHG 2024 (Poster)
Multi-omic profiling of tumor-derived extracellular vesicles enables early cancer detection.
View Poster
Why Choose FYR?
EVs have the potential to revolutionize disease detection, clinical trial design and patient stratification, asset development, and go/no-go decision-making. FYR’s proprietary EVO-Platform™ reduces the signal-to-noise ratio for EVs and can extract valuable, longitudinal insights including disease subtype, treatment response, and disease progression.
-
Novel Technologies
- EVO-Platform™: Comprehensive multiomics approach, combining genomics, transcriptomics, and proteomics data to reveal disease and biomarker insights. Focus on EVs for advanced disease detection and monitoring through both liquid and traditional tissue biopsies.
- SPARCs™: Selective Protein Affinity Reagent Chemistries, designed to isolate specific disease or tissue-associated EV subpopulations, enriching vital biomarkers for more accurate and early disease detection.
- Advanced Machine Learning & Analytics.
-
Helping Answer Your Questions
- Pathways associated with my disease of interest and drug target?
- Better subset of patients suitable more suitable for my drug?
- Markers that can monitor patient response and disease progression?
Are You Ready to SPARC Innovation?
Interested in learning more? We fuel new relationships, collaborations, and strategic partnerships. Let’s kindle the next generation of innovation together. To learn more, fill out our contact form or email bd@fyr.bio.